Blinded and uniform causes of death verification in cancer screening: A major influence on the outcome of a prostate cancer screening trial?

European Journal of Cancer

Volumn 46, Issue 17, 2010, Pages 3061-3067

  Otto, S J ^a   Van Leeuwen, P J ^a   Hoekstra, J W ^b   Merckelbach, J W ^c   Blom, J H M ^d   Schroder F H ^a   Roobol, M J ^a   De Koning, H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b 'S Hertogenbosch ^*  (Netherlands)

^c Consultant Surgeon ^*  (Netherlands)

^d Sint Fransicus hospital   (Netherlands)

Author keywords

Agreement; Cause of death; Death review; ERSPC; Official statistics; Prostate cancer; Sensitivity; Specificity

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER STATISTICS; CAUSE OF DEATH; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; KAPPA STATISTICS; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; PROSTATE CANCER;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NETHERLANDS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78049465045     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.09.026     Document Type: Article

References (23)

1. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
2. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
3. M.J. Roobol, M. Kerkhof, and F.H. Schroder Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
4. H.J. de Koning, J. Blom, and J.W. Merkelbach Determining the cause of death in randomized screening trial(s) for prostate cancer BJU Int Suppl 92 2003 71 78
5. H.H. Dubben Trials of prostate-cancer screening are not worthwhile Lancet Oncol 10 2009 294 298
6. H.D. Sesso, J.M. Gaziano, R.J. Glynn, and J.E. Buring Value of an endpoints committee versus the use of nosologists for validating cause of death Contemp Clin Trials 27 2006 333 339
7. J. Chamberlain, D. Coleman, R. Ellman, and S. Moss Verification of the cause of death in the trial of early detection of breast cancer. UK trial of early detection of breast cancer group. Trial co-ordinating centre Br J Cancer 64 1991 1151 1156
8. L. Nystrom, L.G. Larsson, and L.E. Rutqvist Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee Acta Oncol 34 1995 145 152
9. A.B. Miller, S. Yurgalevitch, J.L. Weissfeld, L. Prostate Colorectal and Ovarian Cancer Screening Trial Project Team Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial Control Clin Trials S21 2000 400S 406S
10. M.H. Robinson, V.C. Rodrigues, and J.D. Hardcastle Faecal occult blood screening for colorectal cancer at Nottingham: details of the verification process J Med Screen 7 2000 97 98
11. M.J. Roobol, W.J. Kirkels, and F.H. Schroder Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, The Netherlands) BJU Int 92 Suppl. 2 2003 48 54
12. P.M. Beemsterboer, R. Kranse, H.J. de Koning, J.D. Habbema, and F.H. Schröder Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam) Int J Cancer 84 1999 437 441
13. P.M. Beemsterboer, H.J. de Koning, and R. Kranse Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam J Urol 164 2000 1216 1220
14. S.J. Otto, I.W. van der Cruijsen, and M.K. Liem Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer Int J Cancer 105 2003 394 399
15. P.C. Albertsen, S. Walters, and J.A. Hanley A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995 J Urol 163 2000 519 523
16. R.M. Hoffman, S.N. Stone, W.C. Hunt, C.R. Key, and F.D. Gilliland Effects of misattribution in assigning cause of death on prostate cancer mortality rates Ann Epidemiol 13 2003 450 454
17. K. Fall, F. Stromberg, J. Rosell, O. Andren, and E. Varenhorst Reliability of death certificates in prostate cancer patients Scand J Urol Nephrol 42 2008 352 357
18. T. Makinen, P. Karhunen, and J. Aro Assessment of causes of death in a prostate cancer screening trial Int J Cancer 122 2008 413 417
19. V.P. Doria-Rose, P.M. Marcus, and A.B. Miller Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials Clin Trials 7 2010 69 77
20. P. Harteloh, K. de Bruin, and J. Kardaun The reliability of cause-of-death coding in The Netherlands Eur J Epidemiol 2010 10.1007/s10654-010-9445-
21. W.C. Black, D.A. Haggstrom, and H.G. Welch All-cause mortality in randomized trials of cancer screening J Natl Cancer Inst 94 2002 167 173
22. C.J. Newschaffer, K. Otani, M.K. McDonald, and L.T. Penberthy Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort J Natl Cancer Inst 92 2000 613 621
23. D.M. Lloyd-Jones, D.O. Martin, M.G. Larson, and D. Levy Accuracy of death certificates for coding coronary heart disease as the cause of death Ann Intern Med 129 1998 1020 1026